Last reviewed 2026-05-29 · How we verify

Iptilimumab

InSightec · Phase 3 active Small molecule ✓ Verified May 2026

Iptilimumab is a Small molecule drug developed by InSightec. It is currently in Phase 3 development.

Iptilimumab is not mentioned in the provided facts. However, based on the information, a 2-sentence factual summary of the study involving pembrolizumab and atezolizumab can be written as follows: Pembrolizumab and atezolizumab are being studied in combination with blood-brain barrier opening using Exablate focused ultrasound for the treatment of non-small cell lung cancer brain metastases. This study, led by InSightec, aims to assess the safety and efficacy of this treatment approach in patients with NSCLC brain mets.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Iptilimumab
Sponsor	InSightec
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Iptilimumab CI brief — competitive landscape report
Iptilimumab updates RSS · CI watch RSS
InSightec portfolio CI

Frequently asked questions about Iptilimumab

What is Iptilimumab?

Iptilimumab is a Small molecule drug developed by InSightec.

Who makes Iptilimumab?

Iptilimumab is developed by InSightec (see full InSightec pipeline at /company/insightec).

What development phase is Iptilimumab in?

Iptilimumab is in Phase 3.

Manufacturer: InSightec — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing